Sun Pharmaceutical Industries Limited
ICICI Prudential Mutual Fund reduced its stake in Sun Pharmaceutical Industries Limited from 3.72% to 3.21%, selling 1,21,98,910 shares.
A leading pharmaceutical manufacturer engaged in developing and marketing branded and generic formulations alongside Active Pharma Ingredients across global markets. The company operates multiple manufacturing facilities worldwide, serving customers through its extensive distribution network. Sun Pharma specializes in therapeutic areas including ophthalmology, cardiology, gastroenterology, and dermatology, combining research-driven innovation with broad-based generics production to serve patients in India and internationally.
India's second-largest AMC by AUM with over Rs 9 lakh crore managed across 80+ schemes. Joint venture between ICICI Bank and Prudential plc. CIO S. Naren is one of India's most recognised value investors, known for contrarian macro calls and rotating across market caps well ahead of consensus. ICICI Pru's quarterly portfolio disclosures are among the most closely watched in the industry.